CORDIS · 643776 · H2020

TREGeneration Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes

Coordinator: INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES (PT)

Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT).We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not oth…

EU contribution
€5.9M
Total cost
€5.9M
Period
2015-01-01 → 2021-12-31
Framework
Horizon 2020 (2014–2020)
Funding scheme
RIA
Call
H2020-PHC-2014-2015
Status
CLOSED

About Horizon 2020 (2014–2020)

Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.

EU contribution: €5.9M awarded to the consortium. The project runs over approximately 7 years from 2015-01-01 to 2021-12-31.

Full record on CORDIS — partners, deliverables, publications, news.

Open on cordis.europa.eu → Grant DOI ↗

Frequently asked questions

Who funds this research project?
This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
What is the EU contribution?
The European Commission contributes €5.9M toward a total project budget of €5.9M.
Which EU programme funds it?
The project is funded under Horizon 2020 (2014–2020), call H2020-PHC-2014-2015.
Who coordinates the project?
The project is coordinated by INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES (PT).
What is the project timeline?
The project runs from 2015-01-01 to 2021-12-31 — approximately 7 years.
Where can I find the full project record?
The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 643776.